Leuven, Belgium – March 23, 2018. Materialise NV (Nasdaq: MTLS) is the first company in the world to receive FDA clearance for software intended for 3D printing anatomical models for diagnostic use. Leading hospitals are adopting integrated 3D printing services as part of their medical practices as they recognize the added value it brings to personalized patient care. Materialise brings nearly three decades of experience in developing medical solutions that help researchers, engineers and clinicians achieve the desired patient outcomes.
Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing software and of sophisticated 3D printing services, today announced its financial results for the fourth quarter ended December 31, 2017.
PLYMOUTH, Michigan – March 6, 2018. Materialise NV (Nasdaq: MTLS) launched a shoulder planner for surgeons with the possibility to plan shoulder arthroplasty cases and order patient-specific shoulder guides, in collaboration with DePuy Synthes. The TRUMATCH® Personalized Solutions Shoulder System, revealed at the AAOS Annual Meeting in New Orleans, marks a further extension of Materialise’s longstanding collaboration with DePuy Synthes, who will distribute the solution in the United States, Canada, Australia, New Zealand and Europe.
Leuven, Belgium – February 12, 2018. Materialise NV (Nasdaq: MTLS) a global leader in 3D Printing, and PTC have partnered to increase the 3D printing capabilities of PTC’s Creo suite of computer-aided design (CAD) software. This collaboration will expand access to 3D Printing and allow manufacturers to more easily integrate 3D printing capabilities into their manufacturing process, signaling another milestone in the increasing adoption of 3D Printing in the manufacturing industry.